Compare RLJ & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | NVCR |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2011 | 2015 |
| Metric | RLJ | NVCR |
|---|---|---|
| Price | $10.88 | $15.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $7.83 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 7.26% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,349,860,000.00 | $655,353,000.00 |
| Revenue This Year | $2.02 | $7.72 |
| Revenue Next Year | $2.54 | $6.74 |
| P/E Ratio | $90.58 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $6.54 | $9.82 |
| 52 Week High | $12.89 | $21.45 |
| Indicator | RLJ | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 37.66 |
| Support Level | $10.68 | $14.84 |
| Resistance Level | $11.78 | $18.43 |
| Average True Range (ATR) | 0.25 | 0.80 |
| MACD | -0.04 | -0.27 |
| Stochastic Oscillator | 28.15 | 8.31 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.